A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Oral Dose Study of SGM-1019 in Healthy Subjects

Trial Profile

A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Oral Dose Study of SGM-1019 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs SGM 1019 (Primary)
  • Indications Inflammatory bowel diseases
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Second Genome
  • Most Recent Events

    • 09 Apr 2018 Results (safety and pharmacodynamics) presented in a Second Genome media release.
    • 09 Apr 2018 According to a Second Genome media release, preclinical data and results from this trial will be presented at the European Association for the Study of the Liver (EASL) International Liver Congress 2018 (on Friday, 13 Apr 2018).
    • 20 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top